Medtronic Lays Out Plans To Achieve 5%+ Annual Growth
Executive Summary
The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.
You may also be interested in...
Medtronic Pushes Completion Of Pivotal Renal Denervation Trial To Late 2022
The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.
Leveling The Playing Field: Edwards Dedicates $100M To Racial Equity
The fund will support financial institutions in underserved communities and promote an economic cycle focused on creating jobs.
Medtronic Looks Beyond The World Of Doctors And Devices In New Approach To Markets
Health warning to global medtechs: The world’s largest medical device company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.